UNSPSC 51142563: Piroheptine hydrochloride

This classification denotes an antiparkinsonian agent with the molecular structure C22H25N.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 4ZM573199N chemically known as 3-(10,11-dihydro-5h-dibenzo(a,d)cyclohepten-5-ylidene)-1-ethyl-2-methyl, hydrochloride, but more commonly known as piroheptine hydrochloride, which bears US NIH Compound Identifier 27844. European Medicines Agency schedules Piroheptine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32954.

Most nations, for tariff and trade purposes, schedule piroheptine hydrochloride under HS 29339990 and SITC 51577. As of Q4 2014, PIROHEPTINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CCN1CCC(=C2C3CCCCC3CCC4C2CCCC4)C1C.CL.

UNSPSC 51142563 Piroheptine hydrochloride is a Commodity code that in recent state and local solicitations maps to pharmaceutical procurement broadly rather than this specific compound. State and local health agencies, counties, and cooperative purchasing alliances are acquiring naloxone, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription fulfillment services—none of which explicitly reference piroheptine hydrochloride. The mismatch suggests that this code designation may not accurately reflect current buying activity, or that piroheptine hydrochloride procurement is not a material part of state and local government purchasing right now. The issuing bodies across recent opportunities include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and cooperative purchasing alliances serving multiple jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, which includes Oregon).

Activity is concentrated in Florida and Texas with multistate cooperative purchasing through Minnesota. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, through quarterly deliveries to the Seminole County Community Health Building. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information on direct contracting between state pharmacy benefit programs and pharmaceutical manufacturers. MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802) on January 20, 2026, with a response deadline of March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities. The code shows limited or misaligned recent activity specific to piroheptine hydrochloride.